COVID-19 mRNA Vaccine Candidate Receives Clinical Trial Approval in China

CanSino Biologics Inc. announced that the National Medical Products Administration approved the clinical trial application of its COVID-19 mRNA vaccine in China. The application was filed by the Company and its subsidiary CanSino (Shanghai) Biotechnology Co., Ltd.

Established in July 2021, CanSino Shanghai is focused on developing an mRNA technology platform.

Previous pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine could induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 variants of concern ("VOC") identified by the WHO, including the Omicron variant.

Additionally, results showed that CanSinoBIO's mRNA vaccine can induce neutralizing antibodies with greater cross-reactivity against VOCs and provide more robust protection against infections caused by the circulating variants than the original strain-based COVID-19 vaccines.

CanSinoBIO confirmed on April 3, 2022, that it would continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia™.

Convidecia (Ad5-nCoV) is a novel recombinant, adenovirus-based, viral vector vaccine for COVID-19.

As of April. 4, 2022, the Convidecia vaccine was available in about ten countries and as a heterologous booster in China and Argentina. It is also the first adenovirus-vectored vaccine to be included in the heterologous vaccination program in China.

Note: This press release was edited for clarity and manually curated for mobile readers.